Lipids, lipid-lowering therapy and diabetes complications

Area of Science:

• Endocrinology
• Cardiology
• Pharmacology

Background:

• Cardiovascular disease (CVD) is the leading cause of death in diabetic patients.
• Statins are first-line therapy for lipid-lowering, but residual risk persists.
• High triglycerides and low HDL-cholesterol are common in diabetes, indicating unmet therapeutic needs.

Purpose of the Study:

• To review the role of fibrates in managing diabetic dyslipidemia and associated complications.
• To explore the potential of fibrates in reducing residual cardiovascular risk.
• To analyze the pleiotropic effects of fibrates on microvascular complications in diabetes.

Main Methods:

• Review of existing clinical trial data (e.g., ACCORD, FIELD studies).
• Analysis of pharmacological mechanisms of fibrates.
• Examination of effects on lipid profiles, cardiovascular events, and microvascular outcomes.

Main Results:

• Fibrates may reduce residual cardiovascular risk, particularly in patients with high triglycerides and low HDL-cholesterol.
• Evidence suggests fenofibrate benefits diabetic retinopathy, reducing laser treatment and macular edema.
• Fibrates may offer benefits beyond lipid-lowering through pleiotropic actions.

Conclusions:

• Fibrates represent a valuable therapeutic option for managing dyslipidemia in diabetes.
• They may mitigate both macrovascular and microvascular complications.
• Further research into their pleiotropic effects is warranted.